Clicky

Citius Pharmaceuticals, Inc.(CTXR)

Description: Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.


Keywords: Medicine Pharmaceutical Drugs Antibiotics Inflammation Catheter Care Products Cancer Care Prescription Products Hemorrhoids Lidocaine Prescription Product Hemorrhoid Acetamides Anti Infective Products Bloodstream Infections

Home Page: www.citiuspharma.com

CTXR Technical Analysis

11 Commerce Drive
Cranford, NJ 07016
United States
Phone: 908 967 6677


Officers

Name Title
Mr. Leonard L. Mazur Co-Founder, CEO, Chairman & Sec.
Mr. Myron Z. Holubiak Co-Founder & Exec. Vice Chairman
Mr. Jaime Bartushak Chief Bus. Officer, CFO & Chief Accounting Officer
Dr. Myron S. Czuczman M.D. Exec. VP & Chief Medical Officer
Mr. Gary F. Talarico Exec. VP of Operations
Ms. Ilanit Allen VP of Investor Relations & Corp. Communications
Dr. Alan Lader Ph.D. Sr. VP & Head of Clinical Operations and Quality Assurance
Mr. Dhananjay G. Wadekar Sr. VP of Bus. Strategy
Mr. Kelly Creighton Ph.D. Exec. VP of Chemistry, Manufacturing & Controls

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 1.2887
Trailing PE: 0
Price-to-Book MRQ: 1.5048
Price-to-Sales TTM: 0
IPO Date: 2017-07-06
Fiscal Year End: September
Full Time Employees: 0
Back to stocks